$TRVI 4 SEC Filings

Filed On	Filing
17 Sep 2026	Form 4: Heffernan Michael Thomas, Director Received 39,473 shares by exercise or conversion ($126K) · Sold 39,473 shares ($596K)
04 Jun 2026	Form 4: Mathers Edward T, Director Granted 35,000 Nonstatutory Stock Option (right to buy)
04 Jun 2026	Form 4: Meeker David P, Director Granted 35,000 Nonstatutory Stock Option (right to buy)
04 Jun 2026	Form 4: Vanlent Anne, Director Granted 35,000 Nonstatutory Stock Option (right to buy)
04 Jun 2026	Form 4: Heffernan Michael Thomas, Director Granted 35,000 Nonstatutory Stock Option (right to buy)
04 Jun 2026	Form 4: Colangelo Dominick, Director Granted 35,000 Nonstatutory Stock Option (right to buy)
20 Feb 2026	Form 4: Cassella James V, Chief Development Officer Granted 215,000 Stock Option (right to buy)
20 Feb 2026	Form 4: Galletta Christopher, See Remarks Granted 35,000 Stock Option (right to buy)
20 Feb 2026	Form 4: Sciascia Thomas, Chief Scientific Officer Granted 85,000 Stock Option (right to buy)
20 Feb 2026	Form 4: Good Jennifer L, Director Granted 675,000 Stock Option (right to buy)
20 Feb 2026	Form 4: Simon Farrell, Chief Commercial Officer Granted 160,000 Stock Option (right to buy)
12 Jan 2026	Form 4: Hastings David C, Chief Financial Officer Granted 375,000 Stock Option (right to buy)
03 Dec 2025	Form 4: Galletta Christopher, See Remarks Received 4,225 shares by exercise or conversion ($2.16K)
13 Jun 2025	Form 4: Mathers Edward T, Director Granted 45,000 Nonstatutory Stock Option (right to buy)
13 Jun 2025	Form 4: Colangelo Dominick, Director Granted 45,000 Nonstatutory Stock Option (right to buy)
13 Jun 2025	Form 4: Heffernan Michael Thomas, Director Granted 45,000 Nonstatutory Stock Option (right to buy)
13 Jun 2025	Form 4: Vanlent Anne, Director Granted 45,000 Nonstatutory Stock Option (right to buy)
13 Jun 2025	Form 4: Meeker David P, Director Granted 45,000 Nonstatutory Stock Option (right to buy)
03 Jun 2025	Form 4: Galletta Christopher, See Remarks Granted 8,550 Performance Stock Option (right to buy)
03 Jun 2025	Form 4: Sciascia Thomas, Chief Scientific Officer Granted 60,000 Performance Stock Option (right to buy)

Comments